CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other ...( VIENNA Va. June 5 /- CEL-SCI Corporat...),Health

VIENNA, Va., June 5 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) announced today that its collaborators at the University of Hawaii reported on data at the annual American Society for Microbiology in Philadelphia, PA. This data demonstrates that vaccines utilizing its L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine technology with specificity for particular Mycobacterium tuberculosis (TB) antigens can elicit immune responses that would be protective against tuberculosis and have the potential to treat swine and other H1N1 influenzas.

The investigators presented data that showed that blood cells from immunized mice produced gamma interferon in response to the vaccine, while the blood cells from mice in the various control groups did not. Gamma interferon, a cytokine that helps regulate the body's immune response, is considered to be a good indicator of protection against TB and other diseases. The production of too many pro-inflammatory cytokines is thought to be a cause of death in the case of H1N1 influenza. It is for this reason that CEL-SCI believes that the L.E.A.P.S. technology, which induces an effective protective immune response without causing excessive amounts of pro-inflammatory cytokines, may be effective against H1N1 influenza.

In prior tests involving L.E.A.P.S. herpes simplex vaccines, CEL-SCI and other researchers showed that the production of gamma interferon was a good indicator for protection against herpes simplex as well. Dr. Borthakur, of the University of Hawaii, reported at the Microbiology Conference that mouse blood cells taken from L.E.A.P.S. TB immunized mice made detectable amounts of gamma interferon within one day of treatment.

Dr. Daniel Zimmerman, the inventor of the technology believes that the data present
'/>"/>